We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Drug Evaluation

Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice

    Jörg J Vehreschild

    † Author for correspondence

    Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Klinisches Studienzentrum Infektiologie II, Kerpener Straße 62, 50937 Köln, Germany.

    Search for more papers by this author

    Email the corresponding author at janne.vehreschild@uni-koeln.de

    &
    Oliver A Cornely

    Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Klinisches Studienzentrum Infektiologie II, Kerpener Straße 62, 50937 Köln, Germany.

    Search for more papers by this author

    Email the corresponding author at oliver.cornely@uni-koeln.de

    Published Online:8 Aug 2006https://doi.org/10.2217/17460913.1.2.161

    Abstract

    Micafungin is a new drug in the echinocandin class and is currently being investigated in Phase III clinical trials. Like other echinocandins, it inhibits 1,3-β-D-glucan synthesis, thus achieving fungicidal activity against virtually all Candida spp., including those resistant to fluconazole, and fungistatic activity against Aspergillus spp. Micafungin sodium is available for intravenous administration only. It has a favorable safety and drug–drug interaction profile. Micafungin has been approved by the US FDA for treatment of esophageal candidiasis and for antifungal prophylaxis during the pre-engraftment phase in patients undergoing hematopoietic stem cell transplantation. Considering the competitive pricing as well as the good tolerability and efficacy, at present micafungin seems to be another choice for both of these indications. Current research has proven micafungin sodium to add a rational and effective option to the antifungal armamentarium, especially in esophageal candidiasis refractory to fluconazole treatment, in those intolerant to triazoles or in patients needing concomitant therapy interacting with triazoles. In addition to the current indications, recent uncontrolled clinical trials have demonstrated a marked success in the treatment of candidemia and invasive candidiasis. Results from in vitro studies, animal models, small clinical trials, as well as the obvious comparison with the more established caspofungin, hint at possible future indications such as invasive aspergillosis and empirical antifungal therapy. However, preclinical data on micafungin is inconsistent and published well-designed clinical studies are scarce. More controlled and sufficiently scaled trials are imperative in order to establish micafungin as a reliable and safe option in clinical practice.

    Bibliography

    • 1  Nucci M, Anaissie E: Revisiting the source of candidemia: skin or gut? Clin. Infect. Dis.33(12),S1959–S1967 (2001).
      Medline CASGoogle Scholar
    • 2  Barrett D: From natural products to clinically useful antifungals. Biochim. Biophys. Acta1587(2–3),S224–S233 (2002).
      Medline CASGoogle Scholar
    • 3  Mycamine (micafungin sodium) For Injection. Fujisawa (2005).
      Google Scholar
    • 4  Angiolella L, Maras B, Stringaro AR et al.: Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic. J. Chemother.17(4),S409–S416 (2005).
      Medline CASGoogle Scholar
    • 5  Nishiyama Y, Uchida K, Yamaguchi H: Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J. Electron Microsc. (Tokyo)51(4),S247–S255 (2002).
      Medline CASGoogle Scholar
    • 6  Borg-von Zepelin M, Zaschke K, Gross U, Monod M, Muller FM: Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy48(3),S148–S153 (2002).
      MedlineGoogle Scholar
    • 7  Calderone R, Suzuki S, Cannon R et al.: Candida albicans: adherence, signaling and virulence. Med. Mycol.38(Suppl. 1),S125–S137 (2000).
      MedlineGoogle Scholar
    • 8  Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME: In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother.46(12),S3846–S3853 (2002).
      Medline CASGoogle Scholar
    • 9  Mikamo H, Sato Y, Tamaya T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother.46(3),S485–S487 (2000).
      Medline CASGoogle Scholar
    • 10  Tawara S, Ikeda F, Maki K et al.: In vitro activities of a new lipopeptide antifungal agent FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother.44(1),S57–S62 (2000).
      Medline CASGoogle Scholar
    • 11  Uchida K, Nishiyama Y, Yokota N, Yamaguchi H: In vitro antifungal activity of a novel lipopeptide antifungal agent FK463, against various fungal pathogens. J. Antibiot. (Tokyo)53(10),S1175–S1181 (2000).
      Medline CASGoogle Scholar
    • 12  Takakura S, Fujihara N, Saito T et al.: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J. Antimicrob. Chemother.53(2),S283–S289 (2004).
      Medline CASGoogle Scholar
    • 13  Heyn K, Tredup A, Salvenmoser S, Muller FM: Effect of voriconazole combined with micafungin against CandidaAspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob. Agents Chemother.49(12),S5157–S5159 (2005).
      Medline CASGoogle Scholar
    • 14  Ostrosky-Zeichner L, Rex JH, Pappas PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother.47(10),S3149–S3154 (2003).
      Medline CASGoogle Scholar
    • 15  Messer SA, Diekema DJ, Boyken L et al.: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol.44(2),S324–S326 (2006).
      Medline CASGoogle Scholar
    • 16  Nakai T, Hatano K, Ikeda F, Shibuya K: Electron microscopic findings for micafungin-treated experimental pulmonary aspergillosis in mice. Med. Mycol.43(5),S439–S445 (2005).
      Medline CASGoogle Scholar
    • 17  Nishiyama Y, Hasumi Y, Ueda K, Uchida K, Yamaguchi H: Effects of micafungin on the morphology of Aspergillus fumigatus. J. Electron Microsc. (Tokyo)54(1),S67–S77 (2005).
      Medline CASGoogle Scholar
    • 18  Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K: Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob. Agents Chemother.47(6),S1995–S1998 (2003).
      Medline CASGoogle Scholar
    • 19  Nakai T, Uno J, Ikeda F et al.: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother.47(4),S1376–S1381 (2003).
      Medline CASGoogle Scholar
    • 20  Choi JH, Brummer E, Stevens DA: Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect.6(4),S383–S389 (2004).
      Medline CASGoogle Scholar
    • 21  Gil-Lamaignere C, Salvenmoser S, Hess R, Muller FM: Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae. Antimicrob. Agents Chemother.48(7),S2730–S2732 (2004).
      Medline CASGoogle Scholar
    • 22  Chandrasekar PH, Cutright JL, Manavathu EK: Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect.10(10),S925–S928 (2004).
      Medline CASGoogle Scholar
    • 23  Petraitis V, Petraitiene R, Groll AH et al.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother.46(6),S1857–S1869 (2002).
      Medline CASGoogle Scholar
    • 24  Clemons KV, Espiritu M, Parmar R, Stevens DA: Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother.49(12),S4867–S4875 (2005).
      Medline CASGoogle Scholar
    • 25  Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK: Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother.52(4),S656–S662 (2003).
      Medline CASGoogle Scholar
    • 26  Hiraoka T, Wakabayashi T, Kaji Y et al.: Toxicological evaluation of micafungin ophthalmic solution in rabbit eyes. J. Ocul. Pharmacol. Ther.21(2),S149–S156 (2005).
      Medline CASGoogle Scholar
    • 27  Ito M, Nozu R, Kuramochi T et al.: Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob. Agents Chemother.44(9),S2259–S2262 (2000).
      Medline CASGoogle Scholar
    • 28  Seidler M, Salvenmoser S, Müller F-M: Effect of micafungin against biofilm of six different Candida spp. Clin. Microbiol. Infect.11(2),S364 (2005).
      Google Scholar
    • 29  Hiemenz J, Cagnoni P, Simpson D et al.: Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother.49(4),S1331–S1336 (2005).
      Medline CASGoogle Scholar
    • 30  Steinbach WJ, Benjamin DK: New antifungal agents under development in children and neonates. Clin. Microbiol. Infect.18(6),S484–S489 (2005).
      Google Scholar
    • 31  Seibel NL, Schwartz C, Arrieta A et al.: Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother.49(8),S3317–S3324 (2005).
      Medline CASGoogle Scholar
    • 32  Ugazio G, Artizzu M, Pani P, Dianzani MU: The changes in some hydrolytic enzymes in carbon tetrachloride-induced fatty livers. Biochem. J.90(1),S109–S116 (1964).
      Medline CASGoogle Scholar
    • 33  Dufour JF, Zimmermann A, Reichen J: Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages. J. Hepatol.20(4),S524–S530 (1994).
      Medline CASGoogle Scholar
    • 34  Alvarez-Leal M, Contreras-Hernandez D, Chavez A et al.: Leukocyte arylsulfatase A activity in patients with alcohol-related cirrhosis. Am. J. Hum. Biol.13(3),S297–S300 (2001).
      Medline CASGoogle Scholar
    • 35  Tenhunen J, Salminen M, Lundstrom K et al.: Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem.223(3),S1049–S1059 (1994).
      Medline CASGoogle Scholar
    • 36  Hebert MF, Smith HE, Marbury TC et al.: Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol.45(10),S1145–S1152 (2005).
      Medline CASGoogle Scholar
    • 37  Sakaeda T, Iwaki K, Kakumoto M et al.: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J. Pharm. Pharmacol.57(6),S759–S764 (2005).
      Medline CASGoogle Scholar
    • 38  Shimoeda S, Ohta S, Kobayashi H et al.: Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol. Pharm. Bull.28(3),S477–S480 (2005).
      Medline CASGoogle Scholar
    • 39  Hebert MF, Blough DK, Townsend RW et al.: Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol.45(9),S1018–S1024 (2005).
      Medline CASGoogle Scholar
    • 40  Hebert MF, Townsend RW, Austin S et al.: Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol.45(8),S954–S960 (2005).
      Medline CASGoogle Scholar
    • 41  Undre NA, Stevenson P, Amakye DD: Rifampicin and ritonavir do not affect the pharmacokinetics of micafungin (FK463), an echinocandin antifungal. Clin. Microbiol. Infect.10(3),S279 (2004).
      Google Scholar
    • 42  Niwa T, Yokota Y, Tokunaga A et al.: Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol. Pharm. Bull.27(7),S1154–S1156 (2004).
      Medline CASGoogle Scholar
    • 43  Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al.: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis.24(10),S654–S661 (2005).
      Medline CASGoogle Scholar
    • 44  de Wet NT, Bester AJ, Viljoen JJ et al.: A randomized, double blind, comparative trial of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol. Ther.21(7),S899–S907 (2005).
      Medline CASGoogle Scholar
    • 45  Krause DS, Simjee AE, van Rensburg C, et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis.39(6),S770–S775 (2004)
      Medline CASGoogle Scholar
    • 46  Villanueva A, Gotuzzo E, Arathoon EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med.113(4),S294–S299 (2002).
      Medline CASGoogle Scholar
    • 47  Pettengell K, Mynhardt J, Kluyts T et al.: Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol. Ther.20(4),S475–S481 (2004).
      Medline CASGoogle Scholar
    • 48  Sirohi B, Powles RL, Chopra R et al.: A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant38(1),S47–S51 (2006).
      Medline CASGoogle Scholar
    • 49  van Burik JA, Ratanatharathorn V, Stepan DE et al.: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39(10),S1407–S1416 (2004).
      Medline CASGoogle Scholar
    • 50  Lortholary O, Kuse E, Chetchotisakd P et al.: Micafungin versus liposomal amphotericin B in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients. Presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Nice, France, 1–4 April 2006.
      Google Scholar
    • 51  Nucci M, Colombo AL, Silveira F et al.: Risk factors for death in patients with candidemia. Infect. Control Hosp. Epidemiol.19(11),S846–S850 (1998)
      Medline CASGoogle Scholar
    • 52  Betts R, Glasmacher A, Maertens J et al.: Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer106(2),S466–S473 (2006).
      Medline CASGoogle Scholar
    • 53  Keating G, Figgitt D: Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs63(20),S2235–S2263 (2003).
      Medline CASGoogle Scholar
    • 54  Kohno S, Masaoka T, Yamaguchi H et al.: A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis.36(5),S372–S379 (2004).
      Medline CASGoogle Scholar
    • 55  Ullmann AJ, van Burik JA, McSweeney P et al.: An open Phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, UK, 10–13 April 2003.
      Google Scholar
    • 56  Denning DW, Marr KA, Lau WM et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. DOI 10.1016/j.jinf.2006.03.003 (2006) (In Press).
      Google Scholar
    • 57  Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M: Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis.42(6),S753–S757 (2006).
      Medline CASGoogle Scholar
    • 58  Laverdiere M, Lalonde RG, Baril JG et al.: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother.57(4),S705–S708 (2006).
      Medline CASGoogle Scholar
    • 59  Powles MA, Liberator P, Anderson J et al.: Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother.42(8),S1985–S1989 (1998).
      Medline CASGoogle Scholar
    • 60  Annaloro C, Della Volpe A, Usardi P, Lambertenghi Deliliers G: Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur. J. Clin. Microbiol. Infect. Dis.25(1),S52–S54 (2006).
      Medline CASGoogle Scholar
    • 101  US clinical trials website www.clinicaltrials.gov
      Google Scholar